On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2016: Volume 21/ Issue 46 Article 6
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 21, Issue 46, 17 November 2016
Afonso, Blot, and Blot: Prevention of hospital-acquired bloodstream infections through chlorhexidine gluconate-impregnated washcloth bathing in intensive care units: a systematic review and meta-analysis of randomised crossover trials

+ Author affiliations

Citation style for this article: Afonso E, Blot K, Blot S. Prevention of hospital-acquired bloodstream infections through chlorhexidine gluconate-impregnated washcloth bathing in intensive care units: a systematic review and meta-analysis of randomised crossover trials. Euro Surveill. 2016;21(46):pii=30400. DOI:

Received:04 December 2015; Accepted:11 July 2016


Hospital-acquired bloodstream infections (HABSI) and the subgroup of central line-associated bloodstream infections (CLABSI) are associated with substantial morbidity, mortality, and healthcare costs in adults and children [1-5], with higher infection rates among hospitalised children [6]. Data from the EPIC II study have shown that of all nosocomial infections in the intensive care unit (ICU), 15% were bloodstream infections (BSI), with CLABSI accounting for 4.7% [7,8]. Due to the substantial impact on patient outcomes and their preventable nature, reduction of HABSI is the emphasis of several patient safety initiatives [9-11].

CLABSI results from catheter tip contamination by commensal skin flora at time of device insertion and later from microorganisms migrating from skin to the catheter tip or lumen [12]. The risk of CLABSI can be reduced by antiseptic skin preparation immediately before catheter insertion and by maintaining asepsis at insertion site and catheter access points [13]. As a substantial proportion of primary BSI originate from vascular access devices, these infections also decrease following preventive interventions targeting CLABSI [14].

Chlorhexidine gluconate (CHG) has broad antimicrobial action, prolonged residual effect, and is the agent of choice for skin disinfection before catheter insertion [13,15,16]. CHG can also be used in basic hygienic care as a liquid bathing agent or as pre-packaged CHG-impregnated washcloths [17].

A substantial number of studies investigated the value of CHG washcloth patient bathing. Three recent systematic reviews summarised the available evidence concerning colonisation and infection rates [18-20]. Low-quality, non-randomised studies demonstrated mixed effects for prevention of BSI. The effect of CHG-impregnated washcloths on hard outcomes such as rates of HABSI and CLABSI in both adult and paediatric ICU patients remains unclear. We performed a systematic review and meta-analysis of randomised-controlled trials to assess the impact of daily care with CHG washcloths on rates of total HABSI and CLABSI in adult and paediatric ICU patients. Subgroup analysis identified the impact on Gram-positive and Gram-negative microorganisms.


Search strategy

The Medline, EMBASE, Cochrane Library and Web of Science databases were systematically searched using combinations of the key terms ‘chlorhexidine’, ‘chlorhexidine impregnated washcloths’, ‘neonatal’, ‘paediatric’ ‘intensive care unit’, ‘bloodstream infection’, ‘catheter related infection’ and ‘randomised controlled trial’ (Box 1-2, Figure 1). The search strategy included publications until end of April 2015. No predefined review protocol was registered.

Box 1

Systematic Review Protocol

Inclusion criteria

  • Randomised controlled trials

  • Adult ICU population

  • Paediatric ICU population

  • Neonatal ICU population

  • Intervention arm including patient bathing with CHG washcloths

  • Control arm including other standard bathing procedures (not with CHG or other antiseptic)

  • Records investigating impact of intervention in HABSI and CLABSI

  • Full text available

Exclusion criteria

  • Descriptive studies

  • Before-and-after design

  • Evidence of confounders such as other interventions implemented at the same time as CHG washcloth bathing (i.e. care bundles)

  • Comparative studies

  • Reviews, systematic reviews and meta-analysis

  • Studies that did not use CHG in the form of washcloths

CHG: chlorhexidine gluconate; CLABSI: central line-associated bloodstream infection; HABSI: hospital-acquired bloodstream infection; ICU: intensive care unit.

Box 2

Search terms used for study selection

1. MEDLINE search (181 titles found, 7 without accessible full text, 159 excluded, 18 duplicates, 4 eligible studies)

  • Chlorhexidine impregnated washcloths AND catheter related bloodstream infection

  • Chlorhexidine impregnated washcloths AND bloodstream infection

  • Chlorhexidine[MeSH Terms] AND infection transmission[MeSH Terms] AND care units, intensive[MeSH Terms]

  • Chlorhexidine[MeSH Terms] AND bath[MeSH Terms] AND pediatric intensive care units[MeSH Terms]

  • Chlorhexidine[MeSH Terms] AND bath[MeSH Terms] AND intensive care unit[MeSH Terms]

  • Chlorhexidine[MeSH Terms] AND care, neonatal intensive[MeSH Terms]

  • Chlorhexidine[MeSH Terms] AND care unit, intensive[MeSH Terms] AND catheter related infection[MeSH Terms]

  • Chlorhexidine wash[MeSH Terms] AND BSI

  • Chlorhexidine impregnated AND CLABSI

  • Chlorhexidine impregnated AND BSI

  • Chlorhexidine impregnated AND Pediatric

  • Chlorhexidine impregnated AND Neonatal

  • Randomized controlled trial[Publication Type]) AND ICU AND Chlorhexidine

  • Randomized controlled trial[Publication Type] AND intensive care unit) AND chlorhexidine impregnated

  • Chlorhexidine[MeSH Major Topic] AND randomized controlled trial[Publication Type] AND ICU

2. EMBASE search (14 titles found, 12 excluded, 2 duplicates)

  • Bath/ and *chlorhexidine gluconate/ and intensive care unit/

  • Chlorhexidine washcloths and intensive care unit).af

  • Chlorhexidine washcloths and neonatal).af

  • Randomized controlled and chlorhexidine

    • 3 Web of Science search (81 studies found, 78 excluded, 3 duplicates)

  • TS=(chlorhexidine AND wash*) AND TS=(intensive care unit)

  • TS=(chlorhexidine AND wash*) AND TS=(pediatric)

  • TS=(chlorhexidine AND wash*) AND TS=(neonatal intensive care)

  • TS=(chlorhexidine AND wash*) AND TS=(BSI)

  • TS=(chlorhexidine AND wash*) AND TS=(CLABSI)

4. Cochrane Library search (15 titles found, 7 excluded, 8 duplicates)

  • 'Randomized* in Publication Type AND chlorhexidine wash* AND "intensive care unit" NOT "oral"NOT "hand" in Trials'

  • 'Randomized* in Publication Type and chlorhexidine bath* and Intensive Care Unit in Trials'

  • 'Randomized* in Publication Type and chlorhexidine bath* and "intensive care unit" and "neonatal" in Trials'

  • 'Randomized* in Publication Type and chlorhexidine bath* and "intensive care unit" and "BSI" in Trials'

  • 'Randomized* in Publication Type and chlorhexidine washcloth and "intensive care unit" in Trials'

BSI: bloodstream infection; CLABSI: central line-associated bloodstream infection; HABSI: hospital-acquired bloodstream infection; ICU: intensive care unit.

Figure 1

Study selection according to online databases


BSI: bloodstream infection; CHG-WC: chlorhexidine gluconate washcloth; CLABSI: central line-associated bloodstream infection; ICU: intensive care unit; RCT: randomised controlled trial.

Study selection

Eligible studies included randomised trials done in adult, paediatric and neonatal ICUs that compared the impact of daily bathing with CHG washcloths with that of non-antiseptic impregnated washcloths or other standard bathing procedures on HABSI rates. Languages were restricted to English, French, Dutch and Portuguese. The primary outcome measure was number of HABSIs per patient-days. One reviewer performed study selection and consensus was achieved between two reviewers. Search results were screened by title and abstract. Selected papers underwent a full-text assessment and eligibility issues were resolved between reviewers (EA, KB, SB).

Data extraction and quality assessment

Extracted data included study setting, design and sample size, implemented interventions, definitions and primary outcome data on rates of CLABSI and HABSI per patient-days in the treatment and control groups from the intention-to-treat populations. Data were manually calculated when necessary. Secondary outcome measures included Gram-positive and Gram-negative aetiology, study-related adverse events and number of catheter-days and patients. When available, the protocols were examined for discrepancies between original study objectives and the published data. Two independent reviewers performed data extraction and independently assessed the methodological quality of included studies using the Cochrane risk-of-bias assessment tool (EA, KB) [21].

Statistical analysis

A random-effects meta-analysis using the inverse variance method obtained odds ratios (OR) and 95% confidence intervals (CI) for total HABSI rates per 1,000 patient-days. A random-effects model was chosen to encompass clinical heterogeneity in baseline standards of care between ICUs. Heterogeneity was predefined and assessed through the I2 test (I2 ≤ 25% for low, 25% < I2 < 50% for moderate and I2 ≥ 50% for high). Predefined subgroup analysis and meta-regression were performed on HABSI subtype (CLABSI and non-central line HABSI) and pathogen subtype (Gram-negative and Gram-positive). Sensitivity analysis assessed the impact of varying incidence rate denominator data (number of catheter-days and patients) and the removal of studies with a high risk of bias. Assessment of publication bias by funnel plot was planned when considered meaningful (i.e. at least 10 studies included). Review Manager version 5.2.0 was used for meta-analysis models and Comprehensive Meta Analysis version 2.0 was used to perform meta-regression. A p value ≤ 0.05 was considered statistically significant.


The search strategy yielded 291 records. Following title, abstract and full-text assessment, four papers were included for meta-analysis (Figure 2) [22-25], and one study was excluded because it had an inappropriate non-randomised study design. The included studies were non-blinded cluster-randomised crossover trials involving, together, 22,850 patients from 15 adult and 10 paediatric ICUs (Table 1). The treatment group included daily patient bathing with 2% CHG washcloths. Control groups applied daily bathing with non-antiseptic impregnated washcloths or other non-medicated standard bathing procedures in ICUs with comparable baseline infection rates.

Figure 2

Summary of literature search and study selection (n = 291)


CHG: chlorhexidine gluconate.

Table 1

Summary of included studies (n = 4)

Study Setting Sample size Intervention group Control group Primary outcome Secondary outcome Results
Climo (2013) [ 22 ] 9 ICU and bone marrow transplant units 7,727 patients CHG-WC daily bathing Daily bath with non-medicated washcloths Primary, secondary, and central line-associated BSI Primary HABSI and CLABSI microorganisms Control: 88 primary HABSI, 43 CLABSI, 34 secondary HABSI for 25,000 patient-days.
Intervention: 69 primary HABSI, 21 CLABSI, 29 secondary HABSI for 24,931 patient days.
Noto (2015) [ 23 ] 5 adult ICUs (neurological, trauma, surgical, medical, cardiovascular) 9,340 patients CHG-WC daily bathing Non-medicated washcloths Combined primary and secondary HABSI, and CLABSI Combined primary, secondary HABSI, and CLABSI microorganisms Control: 113 primary and secondary HABSI, 4 CLABSI for 20,721 patient-days.
Intervention: 96 primary and secondary HABSI, 4 CLABSI for 19,202 patient days.
Bleasdale (2007) [ 24 ] 1 medical ICU 836 patients CHG-WC daily bathing Soap and water bathing Combined primary HABSI and CLABSI, and secondary HABSI Combined primary HABSI and CLABSI microorganisms Control: 21 CLABSI, 1 primary HABSI, 5 secondary HABSI for 2,119 patient days.
Intervention: 9 CLABSI, 0 primary HABSI, 5 secondary HABSI for 2,210 patient days.
Milstone (2013) [ 25 ] 10 paediatric ICUs 4,947 patients CHG-WC daily bathing Either soap and water or non-medicated washcloths Combined primary and secondary HABSI, and CLABSI Combined primary HABSI and CLABSI microorganisms Control: 79 primary and secondary HABSI, 28 CLABSI for 16,024 patient days.
Intervention: 53 primary and secondary HABSI, 13 CLABSI for 15,057 patient days.

ICU: intensive care unit; BSI: bloodstream infection; CHG-WC: 2% chlorhexidine gluconate washcloth; CLABSI: central line-associated bloodstream infection; HABSI: hospital-acquired bloodstream infection.

The four included studies compared daily 2% CHG washcloth patient bathing with a control arm applying washcloths not impregnated with CHG: non-medicated washcloths [22,23], soap and water [24] or not further specified non-medicated standard bathing procedures [25]. Climo et al. performed their study in nine medical adult ICUs and bone marrow transplantation units [22] and Bleasdale et al. performed a single-centre study in a medical ICU [24]. Milstone et al. studied the intervention impact in 10 paediatric ICUs [25]. Noto et al. selected five adult ICUs in the same institution (cardiac, trauma, neurological, medical and surgical) [23]. Total HABSI rates in the control arm were comparable between the three multicenter studies (5.5–6.6 HABSI per 1,000 patient-days) [22,23,25], with one study reporting twice larger infection rates (12.2 HABSI per 1,000 patient days) in a single ICU [24]. The rates of CLABSI in the control arm varied per study between 0.19 [23], 1.7 [22,25] and 9.9 CLABSI per 1,000 patient days [24].

All 25 units were randomly assigned to either a treatment or a control group. Duration of study period was 10 weeks [23], 6 months [22,25], and 6 or 7 months in both control and treatment groups [24]. Three of the four studies applied washout phases between control and treatment study periods, lasting two [23,24] or six weeks [25]. The study by Climo et al. did not include a washout phase between intervention and control study periods [22]. Three of the studies reported that nurses received training on how to perform bathing and how to identify adverse events related or unrelated to the treatment [22,24,25]. All four trials were non-blinded to patients, caregivers and staff.

Climo et al., Bleasdale et al. and Noto et al. included all admitted adult patients in the ICUs who agreed to participate except those with adverse skin conditions [22-24]. Eight patients refused to participate in the study by Climo et al. and were not included in the final analysis [22]. Bleasdale et al. excluded three patients who lacked skin integrity, declined participation or developed a skin rash. However, these patients were included in the final intention-to-treat analysis [24]. Milstone et al. used an intention-to-treat approach when selecting paediatric patients for analysis. All children admitted in the paediatric ICU were eligible for this study except those younger than two months, those with a present epidural or lumbar drain, skin disease, burns or CHG allergy or those without parental consent. The intention-to-treat population included all children older than two months with an informed consent to participate, whereas the per-protocol population included all the children who received treatment and were not excluded because of adverse reactions [25]. Finally, Noto et al. stated that all admitted patients were randomised and patients admitted during the washout periods were excluded [23].

Climo et al. and Noto et al. defined primary HABSI as a BSI detected at least 48 hours after admission without an attributable secondary source of infection. Bleasdale et al. used the 1988 definitions from the United States Centers for Disease Control and Prevention (CDC) for nosocomial infections for HABSI and CLABSI [26]. These criteria require catheter cultures to define central line bloodstream infections, as opposed to more recent CLABSI definitions of a HABSI occurring in in a patient with a central line (within 48 hours) with no other clear infectious source. Climo et al. and Noto et al. applied the CDC and National Healthcare Safety Network (NHSN) definitions for CLABSI and HABSI [27]. Noto et al. reported combined primary and secondary HABSI rates. Milstone et al. likewise applied CDC/NHSN definitions, however they defined their bloodstream infections by any single positive blood culture, including for commensal skin microorganisms [25]. The authors justified the adjusted definition criteria by stating that morbidity from bacteraemia is significant in critically ill children. Microorganisms identified as Gram-positive or Gram-negative were isolated from combined primary BSI and CLABSI [22,24,25] or from total HABSI [23].

Three studies evaluated study-related adverse events associated with the use of CHG washcloths [22,24,25], but none reported serious adverse events. Milstone et al. specified the occurrence of skin reactions in 69 (2%) patient admissions, with a greater percentage occurring in the treatment group than in the control group (n = 43 (3%) vs n = 26 (1%); p < 0.0001). Only 28% (12/43) of these reactions were considered to be due to CHG washcloths. Crude incidence of CHG-related adverse events was 1.12 per 1,000 patient-days (95% CI: 0.06–2.02) [25]. One study found a higher overall incidence of skin reactions in the control group (n = 130 (3.4%)) rather than the intervention arm (n = 78 (2%)), with all reactions considered not related to the CHG washcloth bathing intervention [22]. Bleasdale et al. reported three cases of skin reaction in the intervention group, which were likewise not attributed to CHG washcloth use [24]. The study by Noto et al. did not report any adverse events [23]. Only the study by Bleasdale et al. studied the minimum inhibitory concentration (MIC) for chlorhexidine resistance of microorganisms in the control and intervention arms, however neither the data nor significance values were reported.

Risk of bias assessment was performed using the Cochrane Collaboration tool for risk of bias assessment (Table 2) [21]. Besides the inability to blind the intervention to patients and staff and the lack of compliance measurements for interventions or baseline hygienic practices in all studies, the main confounder that introduced a high risk of bias was the simplified definition applied by Milstone et al. for their paediatric population. In that study, only one positive blood culture was required to diagnose a bloodstream infection, including commensal skin microorganisms. In the same vein, none of the included articles reported diagnostic methods of catheter or blood culturing. Other sources of bias included lack of a washout phase and no mention of outcome assessment blinding in the Climo et al. study. Issues that confounded generalisability include higher HABSI rates in the Bleasdale et al. trial and lower HABSI rates and shorter mean length of stay in the Noto trial.

Table 2

Cochrane risk-of-bias assessment of included studies (n = 4)

Climo (2013) [22] Noto (2015) [23] Bleasdale (2007) [24] Milstone (2013) [25]
Random sequence generation and allocation concealment Investigators were unblinded to intervention assignment. No mention of blinding of outcome assessments. Infection control personnel responsible for adjudicating infection outcomes were blinded to the treatment assignments. One of three reviewers was blinded to intervention assignment. To avoid bias, infection rates were calculated with a computer algorithm on a data warehouse. Investigators were unblinded to intervention assignment. Outcome assessors were masked to random allocations.
Selection bias Medium risk Low risk Low risk Low risk
Blinding of participants and personnel Due to the nature of the study, none of the studies could blind intervention to staff or patients.
Blinding of outcome assessment Investigators were unblinded to intervention assignment. No mention of blinding of outcome assessments. Infection control personnel responsible for adjudicating infection outcomes were blinded to the treatment assignments. Two reviewers were unblinded to intervention assignment; a third reviewer was blinded. To avoid bias, infection rates were electronically calculated using a computer algorithm on a data warehouse. Investigators were unblinded to intervention assignment. Outcome assessors were masked to random allocations.
Performance bias Medium risk Low risk Low risk Low risk
Incomplete outcome data Reported cost-effectiveness outcomes did not coincide with the protocol. Adverse events reported. Chlorhexidine susceptibility testing was reported. No compliance reporting. Reported primary and secondary outcomes coincided with the protocol. No data on chlorhexidine resistance. No compliance reporting. Reported primary and secondary outcomes coincided with the protocol. Adverse events reported. Chlorhexidine susceptibility testing was reported. No compliance reporting. Reported primary and secondary outcomes coincided with the protocol. Adverse events reported. No data on chlorhexidine resistance. No compliance reporting.
Detection bias Low risk Low risk Low risk Low risk
Selective reporting Cost-effectiveness data not mentioned in the study report but mentioned in the study protocol. Only intention-to-treat group reported. Intention-to-treat and as-treated group analysis provided. Adverse events not reported. Only an intention-to-treat analysis was performed. Three patients excluded from the CHG bathing procedure were considered part of the intervention arm. Per protocol and intention-to-treat group analysis provided.
Attrition bias Low risk Low risk Low risk Low risk
Other sources of bias Sage Products supplied the washcloths, technical and educational support, but was not involved in the study design, analysis or manuscript preparation. Single-centre study with lower baseline HABSI rates and length of stay compared with other included studies. Single-centre study with higher baseline CLABSI rates compared with other studies. Different institutions’ ethics committees decided how to obtain informed consent. BSI criteria required only one blood culture for commensal microorganisms.
Other bias Low risk High risk Medium risk High risk

BSI: bloodstream infection; CHG: chlorhexidine gluconate; CLABSI: central line-associated bloodstream infection; HABSI: hospital-acquired bloodstream infection.

Meta-analysis was performed on the randomised crossover trials to assess the impact of CHG washcloth bathing. A reduction in the rate of total HABSI was associated with CHG washcloth bathing (OR: 0.74; 95% CI: 0.60–0.90; p = 0.002, Figure 3) with moderate statistical heterogeneity (I2 = 36%). One study did not demonstrate a rate reduction of total HABSI [23].

Figure 3

Meta-analysis of the impact of chlorhexidine gluconate washcloth bathing on total rate of hospital-acquired bloodstream infections per patient-days (n = 4 studies)


CHG bathing: chlorhexidine-impregnated washcloth bathing; CI: confidence interval; control: bathing with non-impregnated washcloths.

In Climo et al.’s study, CLABSI rate was 53% lower in the CHG washcloth group than in the control group [22]. Bleasdale et al. described a lower CLABSI risk in the CHG washcloth group than in the control group [24]. Milstone et al.’s study on paediatric patients found a decreased incidence of BSI in patients with a central line (p = 0.03). However, CHG washcloth bathing was not associated with a significantly decreased incidence of CLABSI (p = 0.08) [25]. Noto et al. did not report a significant impact of using CHG washcloths on the rates of CLABSI [23].

Subgroup analysis found a significant reduction in CLABSI (OR = 0.50; 95% CI: 0.35–0.71; p ≤ 0.001, Figure 4) and non-central line-associated HABSI rates per 1,000 patient days (OR = 0.82; 95% CI: 0.70–0.97; p = 0.02). Both subgroups displayed lower heterogeneity compared with the total HABSI rate reduction (I2 = 0%), demonstrating that heterogeneity between studies is partially explained by which infectious outcome is being studied. The effect of CHG washcloth bathing was more pronounced for CLABSI prevention and the difference in impact was significant (p = 0.01). Three of the four studies reported the cultured microorganisms for combined primary and central line-associated HABSI, while the Noto study reported data on combined primary and secondary HABSI [25]. Subgroup analysis found a significant decrease in Gram-positive (OR = 0.55; 95% CI: 0.31–0.99; p = 0.05) but not Gram-negative HABSI (OR = 0.83; 95% CI: 0.59–1.17; p = 0.68) (Figure 5). Meta-regression did not identify a significant difference between Gram-positive and Gram-negative subgroups.

Figure 4

Subgroup analysis of rates of central line-associated bloodstream infection and non-central line-associated hospital-acquired bloodstream infection per patient days (n = 4 studies)


BSI: bloodstream infection; CHG bathing: chlorhexidine-impregnated washcloth bathing; CI: confidence interval; CLABSI: central line-associated bloodstream infection; control: bathing with non-impregnated washcloths.

Figure 5

Subgroup analysis of rates of hospital-acquired Gram-positive and Gram-negative bloodstream infections per patient days (n = 4 studies)


BSI: bloodstream infection; CHG bathing: chlorhexidine-impregnated washcloth bathing; CI: confidence interval; control: bathing with non-impregnated washcloths.

Noto et al. reported microorganism data on combined primary and secondary hospital-acquired bloodstream infection [23].

A funnel plot was not created due to the small number of included studies. Sensitivity analysis compared meta-analysis results for varying denominators per HABSI. The intervention effect per number of patients was comparable for total HABSI (OR = 0.73; 95% CI: 0.58–0.91; p = 0.006), CLABSI (OR = 0.50; 95% CI: 0.35–0.71; p = 0.0001) and non-central line HABSI (OR = 0.82; 95% CI: 0.68–0.97; p = 0.02). Three trials demonstrated that the overall effect on CLABSI per catheter-days was similar (OR = 0.52; 95% CI: 0.36–0.74; p = 0.0003) with one study demonstrating a non-significant decrease [25]. The definitions of HABSI in the paediatric population of Milstone et al. required only one blood culture, even in the case of skin commensals. After exclusion of this high-risk-of-bias study, meta-analysis identified a reduction of the total HABSI (OR = 0.76; 95% CI: 0.59–0.99; p = 0.04) and CLABSI rate per patient days (OR = 0.50; 95% CI: 0.33–0.76; p = 0.02), and the rate reduction for non-central line HABSI, Gram-positive and Gram-negative HABSI became non-significant. The difference between CLABSI and non-central line HABSI remained significant after removal of this high-risk-of-bias trial (p = 0.02).


This meta-analysis of four trials, involving 25 ICUs and 22,850 patients, provides evidence that daily patient bathing with CHG washcloths can reduce the incidence of HABSI. This effect appears mainly to be due to a reduction in CLABSI, possibly based on eradication of Gram-positive skin commensals. After removal of a high-risk-of-bias study, the intervention impact in the Gram-positive and non-central line-associated HABSI subgroups became non-significant. No significant adverse skin events were reported as related to CHG washcloth bathing. One study planned a cost-effectiveness analysis per protocol, but did not report this in the final publication [22]. Among the four studies, significant reductions in individual infection rate were demonstrated for total HABSI (n = 3) and for the subgroups of Gram-positive HABSI (n = 3) and CLABSI (n = 3). The subgroup analysis of non-central line HABSI demonstrated rate reductions, however no single study could independently demonstrate significance. Only Noto et al consistently reported non-significant results: in contrast to the other included studies, their CLABSI rate did not change, with broad CIs [23]. A possible explanation could be the infection rate in the control group (0.19 CLABSI per 1,000 patient-days), which was at least 10 times lower compared with other trials [22,25], and the mean length of stay of 2.5 days, approximately half that of the other included studies [22,24,25].

Two previous systematic reviews had found evidence of the preventive effect of CHG washcloth bathing for CLABSI [18] and HABSI [20]. Another could not conclude that CHG washcloth bathing could reduce BSI rates [19]. However, the majority of included studies were low-quality non-randomised before–after studies, did not focus solely on ICU patients, and applied different CHG bathing interventions. In contrast, this review focused on non-rinse CHG washcloth bathing to prevent HABSI in ICUs, including pediatric ICUs.

Strengths of this meta-analysis comprise the comprehensive search strategy, inclusion of high-quality randomised crossover trials, risk-of-bias assessment, random-effects meta-analysis with subgroup analysis of HABSI and pathogen subtypes, low statistical heterogeneity in the HABSI types subgroup analysis and sensitivity analysis of high-risk-of-bias studies and denominator data. Limitations include non-blinding to the intervention, partially compensated by the crossover design, lack of compliance measurements and lack of reporting of baseline hygienic practices. Since all four included trials were carried out in critically ill patients with a high level of dependency on staff, patient self-reporting of compliance and tolerance was not performed. One trial did not report blinding of outcome assessment and lacked a washout period [22] and another was single-centre, even though it included two geographically distinct units that permitted a randomised crossover design [24].

Clinical and methodological heterogeneity stemmed from differing infection rates, varying methods of reporting HABSI types and definition criteria of HABSI in the paediatric study. Different baseline standards of care leave more or less room for improvement and HABSI prevention, which can influence the perceived effect of the CHG washcloth intervention. The Bleasdale study had higher rates of HABSI in the control arm and the Climo study higher rates of CLABSI, compared with other hospital settings. This could have produced interpretation and applicability bias in that a situation with more room for improvement in healthcare quality may predispose the infection rate reduction to be stronger [24]. Nevertheless, in the subgroup analysis of central line and non-central line HABSI, the heterogeneity between studies decreased (I2 = 0%), indicating that the intervention effect was related to a proportional decrease in HABSI of central line or non-central line origin. An important source of methodological heterogeneity was the Milstone study due to their definition of bacteraemia as one, instead of two, positive blood culture of commensal skin organisms [25]. According to the current evidence, commensal Gram-positive bacteria cause a large proportion of BSI in children; however, they frequently contaminate blood cultures [28,29]. This change in HABSI definition means that the observed intervention effect may represent a false reduction in the yield of contaminated blood cultures that was due to a decrease in commensal skin flora and not to a reduction in bloodstream infections. After removal of this high-risk-of-bias study, a significant reduction was still maintained for total HABSI rates and particularly for the CLABSI subgroup.

The main purpose of patient safety strategies should be to improve quality of care by reducing the clinical and economic burden of healthcare-associated infections. Studies performed in the pre-surgical context have proven the cost-effectiveness of CHG washcloths for preventing surgical site infection [30]; it is unknown if this could be replicated in the ICU context. Studies have hypothesised that CHG washcloth bathing is potentially cost-effective through prevention of CLABSI and that nurses preferred this method over non-washcloth bathing [31-33].

An important concern raised regarding application of antiseptics is the potential selection of antiseptic-resistant pathogens, which should be monitored when introducing universal decolonisation strategies [34]. Only one study measured CHG MIC values between treatment arms, but reflected that the overall increase in resistance in the chlorhexidine group could represent a reduction in isolates that are inhibited by very low CHG concentrations [23].


This meta-analysis provides evidence that the use of CHG washcloths prevents HABSI in ICUs. The impact of CHG washcloth bathing appeared to be primarily due to its prevention of CLABSI. This effect was beneficial and comparable for CLABSI in all four studies. The reduction was possibly due to the reduction of commensal Gram-positive skin microorganisms. However, since the rate reduction was primarily due to Gram-positive bacteria, the possibility still remains that the intervention effect is partially explained by a reduction in blood culture contamination. Hospitals with high baseline hygienic standards of care and lower CLABSI rates may benefit less from CHG washcloth bathing; rather, the intervention can work as a ‘safety net’ when basic hygienic preventive measures are breached. Further research should apply separate classifications of primary, secondary and central line-associated HABSI types, should report catheter cultures to diagnose bloodstream infections to increase certainty and lower the risk of bias due to improper attribution of blood culture contaminants, should report baseline hygienic standard of care practices and should attempt to measure compliance with the daily CHG washcloth bathing intervention. A cost-effectiveness analysis can assess the added benefit of CHG washcloth bathing, taking into account differing standards of care.

Conflict of interest

None declared. SB holds a research mandate of the Special Research Fund at Ghent University.

Authors’ contributions

EA and KB conceived of and designed the study, performed the search of published work, literature search, data acquisition, interpretation and synthesis, independently performed the quality assessment and wrote the paper. In case of doubt regarding inclusion criteria, all investigators had access to the full article. KB performed the statistical analyses. SB conceived of and designed the study, contributed substantially to the search of published work, data interpretation and synthesis and critically revised the final manuscript.


  1. European Antimicrobial Resistance Surveillance System (EARSS). EARSS annual report 2008. Bilthoven: EARSS; 2009. Available from:

  2. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA,  et al.  NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol. 2008;29(11):996-1011. DOI: 10.1086/591861 PMID: 18947320

  3. Umscheid CA, Mitchell MD, Doshi JA, Agarwal R, Williams K, Brennan PJ. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs.Infect Control Hosp Epidemiol. 2011;32(2):101-14. DOI: 10.1086/657912 PMID: 21460463

  4. Blot S, Vandewoude K, Hoste E, Colardyn F. Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa.J Hosp Infect. 2003;53(1):18-24. DOI: 10.1053/jhin.2002.1329 PMID: 12495681

  5. Blot SI, Depuydt P, Annemans L, Benoit D, Hoste E, De Waele JJ,  et al.  Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis. 2005;41(11):1591-8. DOI: 10.1086/497833 PMID: 16267731

  6. Edwards JR, Peterson KD, Mu Y, Banerjee S, Allen-Bridson K, Morrell G,  et al.  National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. Am J Infect Control. 2009;37(10):783-805. DOI: 10.1016/j.ajic.2009.10.001 PMID: 20004811

  7. Vincent J-L, Rello J, Marshall J, Silva E, Anzueto A, Martin CD,  et al.  International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-9. DOI: 10.1001/jama.2009.1754 PMID: 19952319

  8. Verstraete E, Boelens J, De Coen K, Claeys G, Vogelaers D, Vanhaesebrouck P,  et al.  Healthcare-associated bloodstream infections in a neonatal intensive care unit over a 20-year period (1992-2011): trends in incidence, pathogens, and mortality. Infect Control Hosp Epidemiol. 2014;35(5):511-8. DOI: 10.1086/675836 PMID: 24709719

  9. Blot K, Bergs J, Vogelaers D, Blot S, Vandijck D. Prevention of central line-associated bloodstream infections through quality improvement interventions: a systematic review and meta-analysis.Clin Infect Dis. 2014;59(1):96-105. DOI: 10.1093/cid/ciu239 PMID: 24723276

  10. Smith MJ. Catheter-related bloodstream infections in children. Am J Infect Control. 2008;36(10):S173.e1-3.

  11. Centers for Disease Control and Prevention (CDC). Reduction in central line-associated bloodstream infections among patients in intensive care units--Pennsylvania, April 2001-March 2005.MMWR Morb Mortal Wkly Rep. 2005;54(40):1013-6.PMID: 16224448

  12. Safdar N, Maki DG. The pathogenesis of catheter-related bloodstream infection with noncuffed short-term central venous catheters.Intensive Care Med. 2004;30(1):62-7. DOI: 10.1007/s00134-003-2045-z PMID: 14647886

  13. O’Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG,  et al.  Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control. 2002;30(8):476-89. DOI: 10.1067/mic.2002.129427 PMID: 12461511

  14. Eggimann P, Harbarth S, Constantin MN, Touveneau S, Chevrolet JC, Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care.Lancet. 2000;355(9218):1864-8. DOI: 10.1016/S0140-6736(00)02291-1 PMID: 10866442

  15. Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters.Lancet. 1991;338(8763):339-43. DOI: 10.1016/0140-6736(91)90479-9 PMID: 1677698

  16. Garland JS, Buck RK, Maloney P, Durkin DM, Toth-Lloyd S, Duffy M,  et al.  Comparison of 10% povidone-iodine and 0.5% chlorhexidine gluconate for the prevention of peripheral intravenous catheter colonization in neonates: a prospective trial. Pediatr Infect Dis J. 1995;14(6):510-6. DOI: 10.1097/00006454-199506000-00008 PMID: 7667056

  17. Vernon MO, Hayden MK, Trick WE, Hayes RA, Blom DW, Weinstein RA,  et al.  Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med. 2006;166(3):306-12. DOI: 10.1001/archinte.166.3.306 PMID: 16476870

  18. Karki S, Cheng AC. Impact of non-rinse skin cleansing with chlorhexidine gluconate on prevention of healthcare-associated infections and colonization with multi-resistant organisms: a systematic review.J Hosp Infect. 2012;82(2):71-84. DOI: 10.1016/j.jhin.2012.07.005 PMID: 22889522

  19. Derde LPG, Dautzenberg MJD, Bonten MJM. Chlorhexidine body washing to control antimicrobial-resistant bacteria in intensive care units: a systematic review.Intensive Care Med. 2012;38(6):931-9. DOI: 10.1007/s00134-012-2542-z PMID: 22527065

  20. O’Horo JC, Silva GLM, Munoz-Price LS, Safdar N. The efficacy of daily bathing with chlorhexidine for reducing healthcare-associated bloodstream infections: a meta-analysis.Infect Control Hosp Epidemiol. 2012;33(3):257-67. DOI: 10.1086/664496 PMID: 22314063

  21. Higgins JPT, Altman DG, Sterne JAC, editors. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. London: The Cochrane Collaboration; 2011. Available from:

  22. Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt LA,  et al.  Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med. 2013;368(6):533-42. DOI: 10.1056/NEJMoa1113849 PMID: 23388005

  23. Noto MJ, Domenico HJ, Byrne DW, Talbot T, Rice TW, Bernard GR,  et al.  Chlorhexidine bathing and health care-associated infections: a randomized clinical trial. JAMA. 2015;313(4):369-78. DOI: 10.1001/jama.2014.18400 PMID: 25602496

  24. Bleasdale SC, Trick WE, Gonzalez IM, Lyles RD, Hayden MK, Weinstein RA. Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients.Arch Intern Med. 2007;167(19):2073-9. DOI: 10.1001/archinte.167.19.2073 PMID: 17954801

  25. Milstone AM, Elward A, Song X, Zerr DM, Orscheln R, Speck K,  et al.  Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. Lancet. 2013;381(9872):1099-106. DOI: 10.1016/S0140-6736(12)61687-0 PMID: 23363666

  26. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988.Am J Infect Control. 1988;16(3):128-40. DOI: 10.1016/0196-6553(88)90053-3 PMID: 2841893

  27. Centers for Disease Control and Prevention (CDC). Central line–associated bloodstream infection (CLABSI) event protocol. Atlanta: CDC; 2014.

  28. Advani S, Reich NG, Sengupta A, Gosey L, Milstone AM. Central line-associated bloodstream infection in hospitalized children with peripherally inserted central venous catheters: extending risk analyses outside the intensive care unit.Clin Infect Dis. 2011;52(9):1108-15. DOI: 10.1093/cid/cir145 PMID: 21454298

  29. Niedner MF, Huskins WC, Colantuoni E, Muschelli J, Harris JM, Rice TB,  et al.  Epidemiology of central line-associated bloodstream infections in the pediatric intensive care unit. Infect Control Hosp Epidemiol. 2011;32(12):1200-8. DOI: 10.1086/662621 PMID: 22080659

  30. Kapadia BH, Johnson AJ, Issa K, Mont MA. Economic evaluation of chlorhexidine cloths on healthcare costs due to surgical site infections following total knee arthroplasty.J Arthroplasty. 2013;28(7):1061-5. DOI: 10.1016/j.arth.2013.02.026 PMID: 23540539

  31. Huang SS, Septimus E, Kleinman K, Moody J, Hickok J, Avery TR,  et al.  Targeted versus universal decolonization to prevent ICU infection. N Engl J Med. 2013;368(24):2255-65. DOI: 10.1056/NEJMoa1207290 PMID: 23718152

  32. Evans HL, Dellit TH, Chan J, Nathens AB, Maier RV, Cuschieri J. Effect of chlorhexidine whole-body bathing on hospital-acquired infections among trauma patients.Arch Surg. 2010;145(3):240-6. DOI: 10.1001/archsurg.2010.5 PMID: 20231624

  33. Ritz J, Pashnik B, Padula C, Simmons K. Effectiveness of 2 methods of chlorhexidine bathing.J Nurs Care Qual. 2012;27(2):171-5. DOI: 10.1097/NCQ.0b013e3182398568 PMID: 22036832

  34. Pittet D, Angus DC. Daily chlorhexidine bathing for critically ill patients: a note of caution.JAMA. 2015;313(4):365-6. DOI: 10.1001/jama.2014.18482 PMID: 25603492

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.